Aclaris Therapeutics (NASDAQ:ACRS) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a sell rating to a hold rating in a research report sent to investors on Friday.

Separately, HC Wainwright restated a “neutral” rating on shares of Aclaris Therapeutics in a report on Tuesday, September 17th.

Aclaris Therapeutics Trading Down 6.0 %

NASDAQ:ACRS opened at $2.05 on Friday. Aclaris Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.72. The stock has a market capitalization of $146.43 million, a price-to-earnings ratio of -3.94 and a beta of 0.10. The firm has a fifty day simple moving average of $1.49 and a two-hundred day simple moving average of $1.30.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. The firm had revenue of $4.35 million during the quarter, compared to analyst estimates of $8.31 million. Equities analysts predict that Aclaris Therapeutics will post -0.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Aclaris Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ACRS. Mirae Asset Global Investments Co. Ltd. acquired a new position in Aclaris Therapeutics during the 1st quarter valued at about $39,000. SG Americas Securities LLC lifted its holdings in shares of Aclaris Therapeutics by 69.5% in the first quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 13,461 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Aclaris Therapeutics by 5,265.1% during the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 61,602 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Aclaris Therapeutics in the 2nd quarter valued at $119,000. Finally, Assenagon Asset Management S.A. purchased a new stake in Aclaris Therapeutics in the 3rd quarter valued at $214,000. 98.34% of the stock is owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.